Structure Therapeutics reports more Phase 2 data for oral GLP-1
Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.
The biotech said Monday …
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM
For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open.
What happens when patients stop taking GLP-1 drugs? New study reveals real world insights
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.
Persistence With GLP-1 Receptor Agonist Therapy Remains Low Among Those With Overweight, Obesity
THURSDAY, March 12, 2026 — Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter published online March…
Impurity in Some Compounded Tirzepatide ‘Potentially Dangerous,’ Eli Lilly Warns
(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…
Study Looks at Associations Between Semaglutide and Ischemic Optic Neuropathy
THURSDAY, March 12, 2026 — Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds in men and with Wegovy use, according to a study published online March 10 in the British Journal…
Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide
Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.
Switching GLP-1 Medications Is Common, Can Help People Stick With Weight-Loss Treatment
THURSDAY, March 12, 2026 — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the first year of treatment, a new study reports.
What’s more, those patients who do swap GLP-1…
FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes
(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…
GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions
(MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…